Arrowhead Pharmaceuticals Statistics
Share Statistics
Arrowhead Pharmaceuticals has 138.1M
shares outstanding. The number of shares has increased by 10.56%
in one year.
| Shares Outstanding | 138.1M |
| Shares Change (YoY) | 10.56% |
| Shares Change (QoQ) | 10.35% |
| Owned by Institutions (%) | 79.94% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,235 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 13.24M, so 9.59% of the outstanding
shares have been sold short.
| Short Interest | 13.24M |
| Short % of Shares Out | 9.59% |
| Short % of Float | 12.38% |
| Short Ratio (days to cover) | 7.16 |
Valuation Ratios
The PE ratio is -3.87 and the forward
PE ratio is -4.74.
Arrowhead Pharmaceuticals's PEG ratio is
-0.02.
| PE Ratio | -3.87 |
| Forward PE | -4.74 |
| PS Ratio | 653.4 |
| Forward PS | 3.1 |
| PB Ratio | 12.51 |
| P/FCF Ratio | -3.84 |
| PEG Ratio | -0.02 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Arrowhead Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.74,
with a Debt / Equity ratio of 2.75.
| Current Ratio | 6.74 |
| Quick Ratio | 6.74 |
| Debt / Equity | 2.75 |
| Debt / EBITDA | -0.91 |
| Debt / FCF | -0.84 |
| Interest Coverage | -18.58 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $5,830.87 |
| Profits Per Employee | $-984,389.16 |
| Employee Count | 609 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.77M |
| Effective Tax Rate | 0.45% |
Stock Price Statistics
The stock price has increased by -33.47% in the
last 52 weeks. The beta is 0.9, so Arrowhead Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.9 |
| 52-Week Price Change | -33.47% |
| 50-Day Moving Average | 13.66 |
| 200-Day Moving Average | 18.61 |
| Relative Strength Index (RSI) | 61.51 |
| Average Volume (20 Days) | 1,879,644 |
Income Statement
In the last 12 months, Arrowhead Pharmaceuticals had revenue of 3.55M
and earned -599.49M
in profits. Earnings per share was -5.
| Revenue | 3.55M |
| Gross Profit | 3.55M |
| Operating Income | -601.08M |
| Net Income | -599.49M |
| EBITDA | -561.51M |
| EBIT | -580.11M |
| Earnings Per Share (EPS) | -5 |
Full Income StatementBalance Sheet
The company has 102.69M in cash and 510.55M in
debt, giving a net cash position of -407.87M.
| Cash & Cash Equivalents | 102.69M |
| Total Debt | 510.55M |
| Net Cash | -407.87M |
| Retained Earnings | -1.63B |
| Total Assets | 1.57B |
| Working Capital | 142.44M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -462.85M
and capital expenditures -141.47M, giving a free cash flow of -604.32M.
| Operating Cash Flow | -462.85M |
| Capital Expenditures | -141.47M |
| Free Cash Flow | -604.32M |
| FCF Per Share | -5.05 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -16927.06% and -16882.37%.
| Gross Margin | 100% |
| Operating Margin | -16927.06% |
| Pretax Margin | -17247.54% |
| Profit Margin | -16882.37% |
| EBITDA Margin | -15812.81% |
| EBIT Margin | -16927.06% |
| FCF Margin | -17018.3% |
